共发表SCI文章80余篇，其中代表性文章如下：

1.Xue X.*et al., Cryptococcosis by Cryptococcus gattii in China. Lancet Infect Dis.2015 Oct;15(10):1135-1136. (Q1 IF=36.4)

2.Fan X, Chen L, Chen M, Zhang N, Chang H, He M, Shen Z, Zhang L, Ding H, Xie Y, Huang Y, Ke W, Xiao M, Zang X, Xu H, Fang W, Li S, Cao C, Xu Y, Shan S, Wu W, Chen C, Xue X#, Wang L. Pan-omics-based characterization and prediction of highly multidrug-adapted strains from an outbreak fungal species complex. Innovation (Camb). 2024 Jul 31;5(5):100681. (Q1 IF=33.2)

3.Zhou M, Liu L, Cong Z, Jiang W, Xiao X, Xie J, Luo Z, Chen S, Wu Y, Xue X, Shao N, Liu R. A dual targeting antifungal is effective against multidrug-resistant human fungal pathogens. Nat Microbiol. 2024 May;9(5):1325-1339. (Q1 IF=20.5)

4.Chen L, Zhang L, Xie Y, Wang Y, Tian X, Fang W, Xue X#, Wang L. Confronting antifungal resistance, tolerance, and persistence: Advances in drug target discovery and delivery systems. Adv Drug Deliv Rev. 2023 Sep; 200:115007.  (Q1 IF=16.1)

5.Kong X, Cheng L, Dong Z, Huang Y, Xue X#, Wang Z, Wang Y, Zang X, Qian H, Chang L, Wang Y. Rapid Cryptococcus electroporated-lysis and sensitive detection on a miniaturized platform. Biosens Bioelectron. 2024 Apr 15; 250:116096. (Q1 IF=10.7)

6.Tong Y, Zeng Y, Lu Y, Huang Y, Jin Z, Wang Z, Wang Y, Zang X, Chang L, Mu W, Xue X#, Dong Z. Deep learning-enhanced microwell array biochip for rapid and precise quantification of Cryptococcus subtypes. View. 2024 July 18;5(4):20240032.  (Q1 IF=9.7)

7.Zang X, Zhou Y, Li S, Shi G, Deng H, Zang X, Cao J, Yang R, Lin X, Deng H, Huang Y, Yang C, Wu N, Song C, Wu L, Xue X#. Latex microspheres lateral flow immunoassay with smartphone-based device for rapid detection of Cryptococcus. Talanta. 2024 Nov 23; 284:127254. (Q1 IF=5.6)

8.Xue X.*et al., Identification of exosomal miRNAs as diagnostic biomarkers for cholangiocarcinoma and gallbladder carcinoma. Signal Transduct Target Ther. 2020 Jun 12;5(1):77. (Q1 IF=40.8)

9.Zang X, Wang Q, Zhou H, Liu S, Xue X#, COVID-19 Early Prone Position Study Group. Efficacy of early prone position for COVID-19 patients with severe hypoxia: a single-center prospective cohort study. Intensive Care Med. 2020 Oct;46(10):1927-1929. (Q1 IF=27.1)

10.Wang S, Yu H, Gan Y, Wu Z, Li E, Li X, Cao J, Zhu Y, Wang L, Deng H, Xie M, Wang Y, Ma X, Liu D, Chen B, Tian P, Qiu Z, Xian J, Ren J, Wang K, Wei W, Xie F, Li Z, Wang Q, Xue X#, Liu Z, Shi J, Li W, Tian J. Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study. Lancet Digit Health. 2022 May;4(5): e309-e319. (Q1 IF=23.8)

11.Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, Yang Y, Diao L, Lin SH, Mills GB, Zhuang G, Xue X#, Han L. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. 2020 Oct 2;11(1):4946. (Q1 IF=14.7)

12.Lin X, Ma X, Zhao S, Yao J, Han L, Jing Y, Xue X#. Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights. Trends Cancer. 2024 Oct;10(10):920-934.  (Q1 IF=14.3)

13.Tan Y, Gao J, Wu C, Zhao S, Yu J, Zhu R, Zhang Q, Wu G, Xue X#, Wu J. CT Characteristics and Pathologic Basis of Solitary Cystic Lung Cancer. Radiology. 2019 May;291(2):495-501. (Q1 IF=12.1)

14.Dong Z, Yan S, Liu B, Hao Y, Lin L, Chang T, Sun H, Wang Y, Li H, Wu H, Hang X, He S, Hu J, Xue X#, Wu N, Chang L. Single Living Cell Analysis Nanoplatform for High-Throughput Interrogation of Gene Mutation and Cellular Behavior. Nano Lett. 2021 Jun 9;21(11):4878-4886.  (Q1 IF=11.189)

15.Xie M, Lin X, Bao X, Liang Y, Deng H, Song J, Ma X, Zhang X, Yao J, Pan L, Xue X#. Tertiary Lymphoid Structure in Tumor Microenvironment and Immunotherapy of Lung Cancer. Arch Bronconeumol. 2024 Oct;60 Suppl 2: S77-S85. English, Spanish. (Q1 IF=8.7)

16.Chen Y, Fang Z, Tang Y, Jin Y, Guo C, Hu L, Xu Y, Ma X, Gao J, Xie M, Zang X, Liu S, Chen H, Thomas RK, Xue X#, Ji H, Chen L. Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer. Clin Transl Med. 2021 Dec;11(12): e620.  (Q1 IF=8.554)

17.Ma X, Xie M, Xue Z, Yao J, Wang Y, Xue X#, Wang J. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma. Comput Biol Med. 2022 Dec;151(Pt A):106213. (Q1 IF=7.0)

18.Cai MC, Zhao X, Cao M, Ma P, Chen M, Wu J, Jia C, He C, Fu Y, Tan L, Xue X#, Yu Z, Zhuang G. T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment. J Patho.2020 Jun;251(2):147-159.  (Q1 IF=5.979)